INDEPENDENT PERSPECTIVES ON WHOLE-PERSON HEALTHSearch the Journal ↗
Wholistic Health Journal
NEWS, PROVIDERS, AND DESTINATIONS FOR WHOLE-PERSON HEALTH
Sections & searchAll news & research
News
Health & Wellness TopicsFind a ProviderFeatured Providers by StateWellness DestinationsGet MatchedFor ProvidersSearch

Research explainer

When Depression Returns, What Did a Mindfulness Trial Actually Test?

The PREVENT trial compared two years of relapse prevention after recurrent depression. Its design matters for anyone interpreting the result as a reason to change medication.

Wholistic Health Journal ·

Two seated people in conversation.
Two seated people in conversation.

Starting after earlier episodes

Someone who has already recovered from several episodes of depression faces a different question from someone seeking help for symptoms for the first time. The PREVENT investigators recruited adults with at least three previous major depressive episodes who were taking a therapeutic dose of a maintenance antidepressant. Their question was whether a course of mindfulness-based cognitive therapy, coupled with support to reduce or discontinue medication, could extend the time before depression returned compared with continuing maintenance medication. The participants had already reached a particular point in their care before either study strategy began.

What the comparison included

Across 95 UK general practices, the researchers recruited 424 people and assigned equal numbers by chance to the two approaches. The therapy group received a structured psychological treatment as well as support around a potential medication change. Someone downloading a meditation recording or reducing medication alone would be making a different change from the one evaluated here. Participants knew which treatment they received. Researchers who assessed outcomes were kept unaware of the assignment, a design choice that reduced the opportunity for their expectations about therapy or medication to influence those assessments.

Reading the interval

Over two years, the trial found no statistically clear advantage for the therapy strategy in time to relapse or recurrence. The estimated hazard ratio was 0.89, with a confidence interval from 0.67 to 1.18. A value of one would correspond to equal hazards in the groups. The interval on either side matters because the investigators designed the study to find out whether the therapy strategy was superior. An experiment that fails to demonstrate superiority can still leave room for differences that matter to patients. Calling the options interchangeable would claim a degree of precision that these results do not provide.

Decisions the trial leaves with patients

For someone whose medication is working, the research gives substance to a conversation about what another course of care would involve. Is the particular therapy available? Who would support a change and assess whether symptoms were returning? For someone currently experiencing a first episode, the starting circumstances differ enough that this trial cannot supply a treatment comparison. The published finding belongs to people with recurrent depression in primary care who had access to both strategies, including professional support, and whose progress researchers could follow for two years.

Sources & references

Photo: tiyowprasetyo · CC0 1.0

Continue exploring

Related topic · Find a provider · Explore destinations

Stay informed